to maintain an activated partial thromboplastin time (aPTT) of 1.5 to 2.5 times mean of normal range or baseline for lepirudin and 1.5 to 3.0 times mean of normal range or baseline for argatroban. Patients undergoing PCI were excluded. Medical records were retrospectively reviewed by a single investigator and relevant data extracted. Demographic information, indication for DTI therapy, APACHE II (Acute Physiology and Chronic Health Evaluation) score, pertinent laboratory data, and details regarding DTI therapy were recorded. The project was approved by our Institutional Review Board.
The primary efficacy outcome was effective anticoagulation, which was defined as an aPTT ratio of greater than 1.5 in 80% or more of measurements with two or fewer dose increases during the entire course of therapy. Secondary efficacy outcomes included the time to first therapeutic aPTT, percent of aPTTs that were therapeutic, minimum, maximum, and mean aPTT ratio, number of hold orders for a supratherapeutic aPTT, percent of patients requiring a dose adjustment, and the number of dose titration requirements. The primary safety outcome was in hospital major bleeding, which was defined as overt and associated with any of the following: hemoglobin decrease of 2 g/dL or more; transfusion requirements of 2 units or more of packed red blood cells or fresh-frozen plasma; or an intracranial, retroperitoneal, or prosthetic joint bleed. Minor bleeding was the secondary safety outcome and was defined as bleeding that did not meet the criteria for major bleeding. Primary and secondary outcomes were compared between groups. An unpaired t test was used for parametric data while a Fischer's exact and Chisquare test were used for nonparametric data. A p value of less than 0.05 was considered statistically significant.
RESULTS
A total of 90 patients received DTI therapy (argatroban n = 29, lepirudin n = 61) during the study period. Baseline patient information for all patients is shown in Table 1 . The only significant difference between groups was a lower creatinine clearance in the argatroban group. Renal impairment, defined as a creatinine clearance of less than 60 mL/min, occurred in 79.3% of argatroban patients and 62.3% of lepirudin patients. The mean initial argatroban dose was 1.09 ± 0.62 mcg/kg/min and the mean initial lepirudin dose was 0.08 ± 0.05 mg/kg/hr. The overall mean argatroban dose was 0.97 ± 0.67 mcg/kg/min and the mean lepirudin dose was 0.06 ± 0.04 mg/kg/hour. Primary and secondary efficacy outcomes are outlined in Table 2 . The time to first therapeutic aPTT was the only efficacy outcome that differed between groups. Patients in the argatroban group achieved a mean therapeutic aPTT an average of 5.2 hours earlier than the lepirudin group.
Major bleeding, the primary safety outcome, occurred in seven (11.5%) lepirudin patients and three (10.3%) argatroban patients (p = 1.0). For lepirudin patients, the aPTT ratio at the time of the major bleed was less than 2.5 in five patients and above 2.5 in two patients (2.73 and 3.0). The aPTT ratio was less than 3.0 in all argatroban patients at the time of the bleeding event. All patients who suffered a major bleeding event were transfused. Minor bleeding occurred in 37.7% of lepirudin patients and 27.6% of argatroban patients (p = .477).
DISCUSSION
This study compared the outcomes of lepirudin and argatroban therapy over a 2-year period. With the exception of creatinine clearance, the individual patient characteristics were similar across groups. The mean creatinine clearance was significantly lower in the argatroban group perhaps representing a tendency to prefer this DTI in the presence of renal impairment. Over 60% of lepirudin patients did however, have a creatinine clearance of less than 60 mL/min. Of all efficacy outcomes, only the time to first therapeutic aPTT differed between groups (shorter with argatroban therapy). However, the time to first aPTT measurement was a mean of 2.7 hours earlier in the argatroban group, which may account for this difference. It is feasible that the ease of use (i.e. number of holds, dose titrations, etc) may lead a clinician to select one DTI over another. This study found no difference in the percent of therapeutic aPTTs, number of holds for excessive anticoagulation, percent of patients requiring dose titrations and the number of dose titrations per patient between treatment groups.
The frequency of major bleeding was similar between lepirudin and argatroban therapy, 11.5% (n = 7) and 10.3% (n = 3), respectively. The use of lepirudin in patients with renal impairment did not result in an overall increased risk of bleeding. Of the patients with major bleeding, five were surgical (four lepirudin and one argatroban) and one patient was post-cardiac catheterization (argatroban). Because 60% of patients with major bleeding underwent invasive procedures, underlying patient risk factors should be an important consideration in assessing the DTI bleeding risk. Previous investigators found that an increased aPTT ratio was associated with a significant increase in the risk of bleeding (9) . Interestingly the majority of major bleeding events in this study occurred in patients with therapeutic aPTT ratios. Lepirudin and argatroban appear to demonstrate comparable safety and efficacy outcomes. A large, prospective study comparing outcomes of lepirudin and argatroban therapy is needed to identify if clinically meaningful differences between agents exist.
